Phathom Pharmaceuticals, Inc. develops and commercializes treatments for gastrointestinal diseases, with news centered on VOQUEZNA® (vonoprazan), an oral potassium-competitive acid blocker. Company updates commonly cover VOQUEZNA commercialization for GERD, prescription trends, product presentations, clinical and real-world data, and vonoprazan use with antibiotics for H. pylori infection.
Recurring announcements also address financial results, expense discipline, balance-sheet actions, and guidance tied to the company's commercial execution. Phathom's pipeline-related updates include studies evaluating VOQUEZNA in eosinophilic esophagitis and publications or conference presentations involving GERD and non-erosive reflux disease.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Phathom Pharmaceuticals (Nasdaq: PHAT) has announced its participation in two upcoming investor conferences. The first is the 22nd Annual Needham Virtual Healthcare Conference, where a fireside chat is scheduled for April 18, 2023, at 8:45 a.m. EDT, with one-on-one meetings throughout the conference from April 17-20, 2023. The second event is the H.C. Wainwright BioConnect Investor Conference in New York City, featuring a fireside chat on May 2, 2023, at 2:30 p.m. EDT. Investors can access live webcasts and archived recordings of these chats via the company’s website for 90 days post-event. Phathom focuses on novel treatments for gastrointestinal diseases, with exclusive rights to vonoprazan, a potassium-competitive acid blocker.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced favorable feedback from the U.S. FDA that paves the way for a planned resubmission of its erosive esophagitis new drug application (NDA) within this quarter. The approval could facilitate a combined commercial launch of vonoprazan for erosive esophagitis and H. pylori indications in Q4 2023. Following extensive investigations into nitrosamine impurities, Phathom has mitigated the related issues and presented stability data to the FDA. The company remains optimistic about fulfilling all requirements for regulatory approvals by year-end.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported its 2022 financial results, revealing a net loss of $197.7 million, an increase from $143.9 million in 2021. In Q4 alone, losses reached $55 million, influenced by elevated R&D and administrative expenses. Major highlights included positive topline results from a Phase 3 trial for vonoprazan in treating non-erosive gastroesophageal reflux disease (GERD), alongside FDA approvals for related products. A meeting with the FDA is scheduled for March 2023 to discuss resubmission requirements for new drug applications, although the commercial launch is paused due to a nitrosamine impurity issue.